Koths K
Chiron Corporation, Emeryville, USA.
Curr Opin Biotechnol. 1995 Dec;6(6):681-7. doi: 10.1016/0958-1669(95)80112-x.
Recombinant proteins that have survived the challenges of process development and clinical trials are becoming blockbuster medical products. Growth factors, enzymes and antibodies are being improved by mutational approaches, fused with other proteins, and even chemically modified in vitro. Drug development and testing approaches have advanced, and proteins produced in transgenic animals are new becoming available. Future protein products might include cancer vaccines and therapies for a variety of genetic diseases, but alternative treatments involving gene therapy or small synthetic compounds will provide competition.
成功经受住工艺开发和临床试验考验的重组蛋白正成为畅销的医疗产品。生长因子、酶和抗体正通过突变方法得到改进，与其他蛋白融合，甚至在体外进行化学修饰。药物开发和测试方法不断进步，转基因动物生产的蛋白也开始崭露头角。未来的蛋白产品可能包括癌症疫苗和针对多种遗传疾病的疗法，但涉及基因治疗或小型合成化合物的替代疗法也会构成竞争。
